Captor Capital Corp. (“Captor” or the “Company”) (CSE: CPTR; FRANKFURT: NMV; USOTC: NWURF) today announced that it has closed its acquisition of Mellow Extracts, LLC (“Mellow”). Under the deal terms, Captor has acquired 100 per cent of the securities of Mellow Extracts, LLC in exchange for 3,750,000 common shares of Captor at a deemed issue price of $0.20 per common share. Mellow Extracts will produce ultra-premium oil in a state-of-the-art extraction lab facility in Costa Mesa, California. Mellow will provide California state-compliant service-for-hire extraction, as well as co-packing capacities for white label and private label cannabis brands focusing on cannabis extracts. In addition to this, Mellow will provide oils and premium concentrates to Captor’s retail outlets.

“Cannabis processing and manufacturing is an incredibly fast-growing market segment, and we believe Mellow will be an important asset for Captor,” said Captor CEO, John Zorbas. “It is a very exciting time with Mellow’s expansion in Costa Mesa and they fit the profile for Captor’s overall investment strategy in the space.”


Earlier this year, Mellow successfully obtained a Conditional Use Permit (CUP) from the city of Costa Mesa. The CUP application was approved at a public hearing on February 26th and became effective March 5, 2018.  The CUP also permits Mellow to expand their extraction lab and manufacturing facilities. Final tenant improvements on the building are underway with the occupancy permit expected shortly.

“We expect Mellow to carve out a unique position as a supply chain partner between distributors and brands. In advance of Mellow’s extraction facility becoming fully operational, the company has already received approximately $500,000 in monthly purchase orders,” said John MacPhail, CEO, I-5 Holdings, a wholly owned Captor Capital subsidiary.

Mellow Extracts founder and CEO, Matt Longo, has a breadth of experience in the cannabis industry that includes the operation of a successful California medical cannabis delivery service, the design of customized shipping containers for specific use in the regulated commercial cannabis extraction environment and medical cannabis dispensary operations. In addition, for almost a decade Mr. Longo has acted as a consultant in the industry specializing in regulatory compliance and tax structuring.

About Captor Capital

Captor Capital Corp. is a Canadian firm focused on the cannabis sector listed on the Canadian Securities Exchange, the OTC, and the Frankfurt Stock Exchange. A vertically integrated cannabis company, Captor provides recreational and medical marijuana based products to consumers via its leading brands and dispensary locations. Listed on the Canadian Securities Exchange, the OTCUSA, and the Frankfurt Stock Exchange, Captor owns and operates advanced growing facilities which produce consistent high quality contaminant free marijuana for its customers, as well as other high demand cannabis based goods for consumption. The company follows a strategy of acquiring cash flowing established companies and organizations with growth potential that require capital to scale. Captor currently has a number of revenue generating cannabis investments including two wholly owned branded MedMen dispensaries – the world famous West Hollywood location and the showpiece Orange County dispensary in Santa Ana. Captor Capital is currently looking at additional revenue generating investments in the cannabis space and will be updating the market in due course.

Media Contact
Gavin Davidson, Communications
Captor Capital Corp.
705.446.6630
gavin@captorcapital.com

Forward-Looking Statements

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains or refers to forward-looking information, and is based on current expectations that involve a number of business risks and uncertainties. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to availability of investment opportunities, economic circumstances, market fluctuations and uncertainties, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, and the other risks involved in the investment industry and junior capital markets. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. Readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by law.

Source: globenewswire.com

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce its upcoming investor awareness initiatives. MustGrow continues to actively engage its key stakeholders – potential industry partners, shareholders and prospective investors – by increasing awareness of its remarkable natural mustard-derived crop protection products.

TODAY: The Future of Food Investment Conference – SnowCap Ventures
Tuesday, Nov. 24th at 1:50 pm ET
Investors Register Here

Keep reading... Show less

Sales to Commence Immediately at The Apothecarium Phillipsburg

 TerrAscend Corp. (“TerrAscend”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that it has received the final permit from the NJ Department of Health (“NJ DOH”) to dispense medical cannabis from its first dispensary in New Jersey . The 3,500 square-foot dispensary, located at 55 South Main Street in downtown Phillipsburg is situated in the historic Phillipsburg National Bank & Trust building and is the first Alternative Treatment Center (“ATC”) in Warren County .

Keep reading... Show less